[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C][N][Branch1][#Branch1][C][C][C][Ring1][=Branch1][N][C][=C][C][=C][Branch2][Ring1][=Branch2][C][=C][C][Ring1][=Branch1][=N][C][=C][Ring1][#Branch2][C][=C][C][=Branch1][=Branch2][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][F][F][C][=C][C][=C][C][=Branch1][Branch1][=C][Ring1][=Branch1][O][C][#N]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable, nonpeptide somatostatin receptor type 2 (SST2; SSTR2) agonist, with potential growth hormone (GH) secretion-inhibiting and antineoplastic activities. Upon oral administration, paltusotine targets, binds to and activates SSTR2, which leads to an inhibition in the secretion of human growth hormone (hGH) in the pituitary gland and results in decreased production of insulin-like growth factor (IGF-1). This may inhibit IGF-1-mediated cell signaling pathways, and lead to apoptosis. SSTR2 is overexpressed by some neuroendocrine tumor cells, and GH is over-produced in the pituitary gland in acromegaly."}]